Roberts Glore & Co. Inc. IL Sells 63 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Roberts Glore & Co. Inc. IL trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,223 shares of the medical research company’s stock after selling 63 shares during the quarter. Roberts Glore & Co. Inc. IL’s holdings in Charles River Laboratories International were worth $964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of CRL. Wellington Management Group LLP grew its position in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. State Street Corp grew its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after purchasing an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Charles River Laboratories International by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company’s stock valued at $102,079,000 after acquiring an additional 37,753 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CRL has been the topic of a number of recent analyst reports. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Barclays dropped their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $198.36.

Charles River Laboratories International Price Performance

NYSE CRL opened at $176.20 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77. The stock has a market cap of $9.01 billion, a price-to-earnings ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. The company’s 50 day moving average is $169.15 and its two-hundred day moving average is $185.76. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter last year, the business earned $2.46 EPS. The firm’s revenue was down 1.1% compared to the same quarter last year. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 4,400 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).